Explore innovative strategies for identifying and managing multiple sclerosis through expert insights on biomarker-driven care and clinical practices.

Discover the significance of PIRA in multiple sclerosis (MS) and how pharmacists enhance early detection and patient care in MS management.

Learn how MRI, OCT, and CSF markers refine MS diagnosis and monitoring, and why “active” disease matters beyond relapses.

Learn how diffuse neuroinflammation drives progressive MS, how MRI finds paramagnetic rim lesions, and which cognitive and physical tests track disability over time.

Learn how hidden neuroinflammation drives MS progression, why MRI may miss it, and how rim lesions and testing track disability.

MS experts say MRI and current trial endpoints miss “smoldering” progression; emerging biomarkers, 7T imaging, PROs, and CNS-penetrant therapies aim to close gaps.

Why MS relapses aren’t the whole story: experts explain PIRA, the push for remyelination, and how BTK inhibitors may reach the CNS.

Finibrutinib’s phase 3 MS results hint at new hope for relapsing and progressive disease, as experts weigh safety and monitoring.

Experts explore emerging multiple sclerosis treatments, from brain-protective PDE4 inhibitors and remyelination to CAR T, stem cell transplant, and easier anti-CD20 options.

Explore emerging multiple sclerosis treatments, from brain-protective targets and remyelination to CAR-T, stem cell transplants, and more accessible anti-CD20 options.

Explore who drives REMS success—from FDA and manufacturers to pharmacists and patients—and how MS therapy routes shape safety, adherence, and workflow.

Experts weigh EDSS vs patient-reported symptoms in SPMS, urging composite endpoints, MRI insights, and smarter coding to improve therapy access.

Experts debate tracking MS progression beyond EDSS, blending patient-reported symptoms, MRI metrics, and new ICD-10 coding for access.